KAILYN GRAHAM: Open Payments
NPI 1053197525 · CHESTERFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$428 in 22 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $428
Food & beverage: $428
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $135 |
| Lilly USA, LLC | 5 | $104 |
| Sumitomo Pharma America, Inc. | 3 | $64 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Alexion Pharmaceuticals, Inc. | 1 | $22 |
| TMS NeuroHealth Centers Inc. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $18 |
| Novo Nordisk Inc | 1 | $18 |
| Exact Sciences Corporation | 1 | $14 |
Products named: UBRELVY, MOUNJARO, GEMTESA, QULIPTA, SHINGRIX, VRAYLAR, STRENSIQ, TMS NeuroHealth Centers Inc..
Industry payments across MO — which companies pay providers there.
